Patents by Inventor Patricia Andrade-Gordon

Patricia Andrade-Gordon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020142446
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease EOS mRNA is expressed in platelets and leukocytes and more specifically eosinophils. Although this protease is abundantly expressed in ovary, retina and stomach, where it may perform important functions, its expression in platelets and certain cells of the immune system suggests that it may play roles in thrombosis and in the immune process.
    Type: Application
    Filed: January 8, 2002
    Publication date: October 3, 2002
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Gordon
  • Publication number: 20020142447
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease EOS mRNA is expressed in platelets and leukocytes and more specifically eosinophils. Although this protease is abundantly expressed in ovary, retina and stomach, where it may perform important functions, its expression in platelets and certain cells of the immune system suggests that it may play roles in thrombosis and in the immune process.
    Type: Application
    Filed: January 8, 2002
    Publication date: October 3, 2002
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Gordon
  • Publication number: 20020110895
    Abstract: Here we describe the molecular identification of a cDNA encoding a novel serine protease we have termed protease EOS. The deduced amino acid sequence, and it alignment with other well-characterized serine proteases indicates that it is a member of the S1 serine protease family. We have found that the protease EOS mRNA is expressed in platelets and leukocytes and more specifically eosinophils. Although this protease is abundantly expressed in ovary, retina and stomach, where it may perform important functions, its expression in platelets and certain cells of the immune system suggests that it may play roles in thrombosis and in the immune process. Enzymatically active protease EOS is amenable to further biochemical analyses for the identification of physiological substrates and specific modulators.
    Type: Application
    Filed: January 8, 2002
    Publication date: August 15, 2002
    Inventors: Andrew Darrow, Jenson Qi, Patricia Andrade-Gordon
  • Patent number: 6077990
    Abstract: Transgenic mice with a non-functional proteinase activated receptor-2 (PAR2) gene are prepared by targeted disruption of the endogenous PAR2 gene. The resulting transgenic mice display a phenotype including a lack of a hypotensive response to administration of the peptide, SLIGRL, and a reduction in carrageenin-induced paw edema compared to wild type mice.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: June 20, 2000
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Wai-Ping Leung, Andrew Darrow, Patricia Andrade-Gordon
  • Patent number: 5955645
    Abstract: A transgenic animal with alterations in an thrombin receptor gene is prepared by introduction of an altered thrombin receptor gene into a host animal. The resulting transgenic animals do not produce functional thrombin receptor molecules.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: September 21, 1999
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Wai-Ping Leung, Patricia Andrade-Gordon, Lubing Zhou
  • Patent number: 5770575
    Abstract: Nipecotic acid-derived compounds of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: June 23, 1998
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Mary Pat Beavers, Patricia Andrade-Gordon, William J. Hoekstra
  • Patent number: 5130143
    Abstract: A composition for thrombolytic therapy includes a tissue-type plasminogen activator (t-PA) and a low affinity heparin fraction. The composition is administered intravenously to allow the t-PA to dissolve blood clots while the low affinity heparin fraction prevents reocculsion without the harmful side effects observed for unfractionated heparin, such as, stimulation of and interference with t-PA activity in the circulatory system, as well as, interference with fibrinolytic activity which can cause hemorrhaging in the mammalian circulatory system.
    Type: Grant
    Filed: November 4, 1988
    Date of Patent: July 14, 1992
    Assignee: The Research Foundation of State University of New York
    Inventors: Sidney Strickland, Patricia Andrade-Gordon
  • Patent number: 4897444
    Abstract: An immobilized fluorogenic substrate useful in processes for identifying and quantifying, intra- and extra-cellularly, and mammalian body fluids, as well as animal cell abstracts is disclosed. The immobilized fluorogenic substrate has the structureR.sub.1 --NH--R.sub.4 --R.sub.2 --R.sub.3wherein R.sub.1 represents an enzyme-specific oligopeptide; R.sub.2 represents a spacer group which is methylenecarbonyloxy, a methylenecarboxamido, or a methylanesulfonamido group attached to a polymethylene chain which itself has a functional group suitable for coupling with a polymer; R.sub.3 represents a biologically inert polymer; and R.sub.4 represents a fluorogenic moiety.
    Type: Grant
    Filed: June 3, 1985
    Date of Patent: January 30, 1990
    Assignee: The Research Foundation of the State University of New York
    Inventors: Paul J. Brynes, Patricia Andrade-Gordon